희귀 신경퇴행성 질환 치료 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Rare Neurodegenerative Disease Treatment Market size is expected to reach USD 0.96 Billion in 2034 from USD 0.54 Billion (2025) growing at a CAGR of 6.49% during 2026-2034.

The global rare neurodegenerative disease treatment market is witnessing steady growth due to increasing awareness, improved diagnostic capabilities, and advancements in precision medicine. Conditions such as Huntington's disease, amyotrophic lateral sclerosis (ALS), and rare forms of Parkinsonism are gaining more clinical attention, encouraging pharmaceutical companies to invest in research and development. Government support, orphan drug designations, and incentives for rare disease treatments are also significantly contributing to market expansion across developed and emerging regions.

Key drivers of this market include the rising prevalence of genetic neurological disorders, advancements in gene therapy, and increasing collaborations between biotech firms and research institutions. The development of disease-modifying therapies, coupled with innovative drug delivery systems, is accelerating treatment accessibility. Additionally, growing patient registries and advocacy groups are pushing for early diagnosis and better therapeutic solutions, creating a favorable environment for market growth.

Looking ahead, the market is expected to expand rapidly with the integration of personalized medicine and AI-driven diagnostics. Emerging technologies such as CRISPR gene editing and stem cell therapy hold immense potential for treating rare neurodegenerative diseases. Increased clinical trials and regulatory support will further boost innovation, while improved global healthcare infrastructure will enhance treatment reach, especially in underdiagnosed regions.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Treatment Type

• Enzyme Replacement Therapy
• Gene Therapy
• Stem Cell Therapy
• Immunomodulatory Therapy
• Symptomatic Treatment

By Disease Indication

• Alzheimer's Disease
• Parkinson's Disease
• Multiple Sclerosis
• Amyotrophic Lateral Sclerosis
• Huntington's Disease

By Route of Administration

• Oral
• Intravenous
• Intrathecal
• Subcutaneous
• Topical

By Age Group

• Pediatric
• Adult
• Geriatric

By Pharmacology

• Monoclonal Antibodies
• Small Molecules
• Peptides
• Oligonucleotides
• Viral Vectors

COMPANIES PROFILED

• Eli Lilly and Company, , UCB, Roche, Gilead Sciences, Merck, Biogen, Sanofi, Lundbeck, Pfizer, Otsuka Pharmaceutical, GlaxoSmithKline, Novartis, AbbVie, Teva Pharmaceutical Industries
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET: BY TREATMENT TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Treatment Type
• 4.2. Enzyme Replacement Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Gene Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Stem Cell Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Immunomodulatory Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Symptomatic Treatment Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET: BY DISEASE INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Disease Indication
• 5.2. Alzheimer's Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Parkinson's Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Multiple Sclerosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Amyotrophic Lateral Sclerosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Huntington's Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Intrathecal Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Subcutaneous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET: BY AGE GROUP 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Age Group
• 7.2. Pediatric Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Adult Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Geriatric Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET: BY PHARMACOLOGY 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Pharmacology
• 8.2. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Small Molecules Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Peptides Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.5. Oligonucleotides Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.6. Viral Vectors Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Treatment Type
  • 9.2.2 By Disease Indication
  • 9.2.3 By Route Of Administration
  • 9.2.4 By Age Group
  • 9.2.5 By Pharmacology
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Treatment Type
  • 9.3.2 By Disease Indication
  • 9.3.3 By Route Of Administration
  • 9.3.4 By Age Group
  • 9.3.5 By Pharmacology
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Treatment Type
  • 9.4.2 By Disease Indication
  • 9.4.3 By Route Of Administration
  • 9.4.4 By Age Group
  • 9.4.5 By Pharmacology
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Treatment Type
  • 9.5.2 By Disease Indication
  • 9.5.3 By Route Of Administration
  • 9.5.4 By Age Group
  • 9.5.5 By Pharmacology
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Treatment Type
  • 9.6.2 By Disease Indication
  • 9.6.3 By Route Of Administration
  • 9.6.4 By Age Group
  • 9.6.5 By Pharmacology
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL RARE NEURODEGENERATIVE DISEASE TREATMENT INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 UCB
  • 11.2.2 Roche
  • 11.2.3 Gilead Sciences
  • 11.2.4 Merck
  • 11.2.5 Biogen
  • 11.2.6 Sanofi
  • 11.2.7 Lundbeck
  • 11.2.8 Pfizer
  • 11.2.9 Otsuka Pharmaceutical
  • 11.2.10 GlaxoSmithKline
  • 11.2.11 Novartis
  • 11.2.12 AbbVie
  • 11.2.13 Teva Pharmaceutical Industries